Adipose-derived SVF for Erectile Dysfunction
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment for erectile dysfunction (ED) using a single injection of a patient's own fat-derived cells (GID SVF-2). The goal is to determine if this approach is safe and can improve ED symptoms. It suits individuals who have experienced ED for at least three months and have been using ED medication (such as Viagra) but are willing to stop during the study. Participants must have the same sexual partner throughout the trial and speak English. Those who haven't responded to ED medications or have certain medical conditions are not eligible. As an unphased trial, this study provides a unique opportunity to explore innovative treatment options for ED.
Do I have to stop taking my current medications for the trial?
Yes, you will need to stop taking any PDE5 inhibitors (medications for erectile dysfunction) for the duration of the study. If you are currently taking blood thinners, cancer drugs, or HIV drugs, you cannot participate in the trial.
What prior data suggests that this treatment is safe for erectile dysfunction?
A previous study demonstrated that using a person's own fat cells, known as stromal vascular fraction (SVF), was safe when injected into the face for certain treatments. No serious side effects occurred, and some individuals even experienced improvements over time. Another study examined SVF for knee pain and found it was well-tolerated, with no significant negative reactions.
Research has also shown that injecting SVF into the hands of patients with systemic sclerosis was safe, as participants did not report serious issues during the study. These findings support the general safety of SVF injections for various conditions.
While the current study focuses on the safety of SVF for erectile dysfunction, past research suggests that the treatment should be well-tolerated.12345Why are researchers excited about this trial?
Unlike the standard treatments for erectile dysfunction, such as pills, injections, or devices, GID SVF-2 is unique because it uses your body's own cells to help address the issue. Researchers are excited about this treatment because it involves a single injection of autologous adipose-derived stromal vascular fraction (SVF), which is a fancy way of saying it uses cells harvested from your own fat tissue. This approach could potentially repair and regenerate the affected tissues, offering a more natural and potentially longer-lasting solution. While most current treatments focus on symptom management, this innovative method targets the underlying issues, which could mean fewer side effects and a more sustainable improvement in erectile function.
What evidence suggests that this treatment might be an effective treatment for erectile dysfunction?
Research has shown that a treatment called adipose-derived stromal vascular fraction (SVF) therapy, such as GID SVF-2, can reduce pain and improve movement. Studies focused on knee osteoarthritis have demonstrated that SVF treatment significantly decreases pain over time. This trial involves participants receiving a single injection of GID SVF-2, which uses cells from their own fat tissue to reduce inflammation and aid healing. Early results suggest it might also help with other conditions by lowering inflammation. Although limited data exists on its use for erectile dysfunction, its mechanism shows promise for treating various conditions.16789
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single injection of autologous adipose-derived stromal vascular fraction (SVF)
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Monitoring of adverse events
What Are the Treatments Tested in This Trial?
Interventions
- GID SVF-2
Find a Clinic Near You
Who Is Running the Clinical Trial?
GID BIO, Inc.
Lead Sponsor